Brief: Milestone Pharmaceuticals Appoints David Sandoval As General Counsel And Chief Compliance Officer
10/02/2026 15:28
Feb 10 (Reuters) - Milestone Pharmaceuticals Inc MIST.O: MILESTONE PHARMACEUTICALS APPOINTS DAVID SANDOVAL AS GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER Source text: ID:nGNX8L13Vw Further company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview